Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06901232 · ClinicalTrials.gov registry record · NA
Mindfulness-based Neurofeedback to Reduce Negative Thinking in CHARMS Adolescents
A NA study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT06901232: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT06901232 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06901232, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The study will test the hypothesis that mindfulness-based neurofeedback (mbNF) will improve repetitive negative thinking and social and role functioning over sham neurofeedback in adolescents at risk for serious mental illness. To do so, 90 adolescents ages 14-21 with elevated repetitive negative thinking will be enrolled into a double-blind randomized clinical trial of sessions of mindfulness training with either active mindfulness-based neurofeedback or sham neurofeedback and three months of mindfulness practice and follow up.
Primary Outcome
Perseverative Thinking Questionnaire- Child Version (PTQ-C), is a content-independent measure of RNT, with 15 items, rated on a 5- point scale (never, almost never, sometimes, often, almost always), with excellent internal consistency, Cronbach's alpha=0.95, in both clinical and non-clinical samples, validated and normed in clinical and non-clinical adolescent and young adult samples as a transdiagnostic research tool that has been shown to predict MDD. Higher scores indicate greater RNT.
Interventions
- BEHAVIORAL Mindfulness Training
- BEHAVIORAL Active mindfulness-based neurofeedback (Active mbNF)
- BEHAVIORAL Sham mindfulness-based neurofeedback
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2027-09 |
| Est. Completion | 2029-04 |
| Phase | NA |
What is known before NCT06901232 opens enrollment
NCT06901232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Mindfulness Training is the first listed.
NCT06901232 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06901232 about?
NCT06901232 is a clinical study titled "Mindfulness-based Neurofeedback to Reduce Negative Thinking in CHARMS Adolescents". The study will test the hypothesis that mindfulness-based neurofeedback (mbNF) will improve repetitive negative thinking and social and role functioning over sham neurofeedback in adolescents at risk for serious mental illness. To do so, 90 adolescents ages 14-21 with elevated repetitive negative th...
What is the current status of trial NCT06901232?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2027-09. Estimated completion is 2029-04.
What interventions are being tested in trial NCT06901232?
The interventions under investigation include: Mindfulness Training (BEHAVIORAL), Active mindfulness-based neurofeedback (Active mbNF) (BEHAVIORAL), Sham mindfulness-based neurofeedback (BEHAVIORAL).
Who is sponsoring clinical trial NCT06901232?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06901232's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia